MAP kinase signalling pathways in cancer

被引:2514
作者
Dhillon, A. S.
Hagan, S.
Rath, O.
Kolch, W.
机构
[1] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland
[2] Univ Glasgow, Sir Henry Wellcome Funct Genom Facil, Glasgow G12 8QQ, Lanark, Scotland
关键词
MAPK; cancer; signal transduction; oncogenes;
D O I
10.1038/sj.onc.1210421
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Cancer can be perceived as a disease of communication between and within cells. The aberrations are pleiotropic, but mitogen-activated protein kinase (MAPK) pathways feature prominently. Here, we discuss recent findings and hypotheses on the role of MAPK pathways in cancer. Cancerous mutations in MAPK pathways are frequently mostly affecting Ras and B-Raf in the extracellular signal-regulated kinase pathway. Stress-activated pathways, such as Jun N-terminal kinase and p38, largely seem to counteract malignant transformation. The balance and integration between these signals may widely vary in different tumours, but are important for the outcome and the sensitivity to drug therapy.
引用
收藏
页码:3279 / 3290
页数:12
相关论文
共 147 条
[1]
PHORBOL ESTERS STIMULATE THE PHOSPHORYLATION OF C-JUN BUT NOT V-JUN - REGULATION BY THE N-TERMINAL DELTA DOMAIN [J].
ADLER, V ;
FRANKLIN, CC ;
KRAFT, AS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (12) :5341-5345
[2]
Beeram Muralidhar, 2003, Clin Adv Hematol Oncol, V1, P476
[3]
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines [J].
Bloethner, S ;
Chen, BW ;
Hemminki, K ;
Müller-Berghaus, J ;
Ugurel, S ;
Schadendorf, D ;
Kumar, R .
CARCINOGENESIS, 2005, 26 (07) :1224-1232
[4]
p38 MAPK in development and cancer [J].
Bradham, Cynthia ;
McClay, David R. .
CELL CYCLE, 2006, 5 (08) :824-828
[5]
Mechanism of p38 MAP kinase activation in vivo [J].
Brancho, D ;
Tanaka, N ;
Jaeschke, A ;
Ventura, JJ ;
Kelkar, N ;
Tanaka, Y ;
Kyuuma, M ;
Takeshita, T ;
Flavell, RA ;
Davis, RJ .
GENES & DEVELOPMENT, 2003, 17 (16) :1969-1978
[6]
NF-κB and JNK -: An intricate affair [J].
Bubici, C ;
Papa, S ;
Pham, CG ;
Zazzeroni, F ;
Franzoso, G .
CELL CYCLE, 2004, 3 (12) :1524-1529
[7]
p38 MAP kinase's emerging role as a tumor suppressor [J].
Bulavin, DV ;
Fornace, AJ .
ADVANCES IN CANCER RESEARCH, VOL 92, 2004, 92 :95-118
[8]
Loss of oncogenic H-ras-induced cell cycle arrest and p38 mitogen-activated protein kinase activation by disruption of gadd45a [J].
Bulavin, DV ;
Kovalsky, O ;
Hollander, MC ;
Fornace, AJ .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (11) :3859-3871
[9]
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity [J].
Bulavin, DV ;
Demidov, ON ;
Saito, S ;
Kauraniemi, P ;
Phillips, C ;
Amundson, SA ;
Ambrosino, C ;
Sauter, G ;
Nebreda, AR ;
Anderson, CW ;
Kallioniemi, A ;
Fornace, AJ ;
Appella, E .
NATURE GENETICS, 2002, 31 (02) :210-215
[10]
Amino-terminal-derived JNK fragment alters expression and activity of c-Jun, ATF2, and p53 and increases H2O2-induced cell death [J].
Buschmann, T ;
Yin, ZM ;
Bhoumik, A ;
Ronai, Z .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (22) :16590-16596